|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer显示文摘AIM:To investigate feasibility,morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer.METHODS:Patients suffering from locally-advanced(T3-4 any N M0 or any T N1-3 M0)gastric carcinoma,staged with endoscopic ultrasound,bone scan,computed tomography,and laparoscopy,were assigned to receive four 21 d/cycles of TCF(docetaxel 75 mg/m 2 day 1,cisplatin 75 mg/m 2 day 1,and fluorouracil 300 mg/m 2 per day for days 1-14),either before(Arm A)or after(Arm B)gastrectomy.Operative morbidity,overall mortality,and severe adverse events were compared by intention-to-treat analysis.RESULTS:From November 1999 to November 2005,70 patients were treated.After preoperative TCF(Arm A),thirty-two(94%)resections were performed,85% of which were R0.Pathological response was complete in 4 patients(11.7%),and partial in 18(55%).No surgical mortality and 28.5%morbidity rate were observed,similar to those of immediate surgery arm(P= 0.86).Serious chemotherapy adverse events tended to be more frequent in arm B(23%vs 11%,P=0.07),with a single death per arm.CONCLUSION:Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma. | Roberto Biffi Nicola Fazio Fabrizio Luca Antonio Chiappa Bruno Andreoni Maria Giulia Zampino Arnaud Roth Jan Christian Schuller Giancarla Fiori Franco Orsi Guido Bonomo Cristiano Crosta Olivier Huber | 2010 | World Journal of Gastroenterology2010，16，7： | 43 |
| 2 | microRNAs in colon cancer: A roadmap for discovery显示文摘 | Simona Rossi Antonio Fabio Di Narzo Pieter Mestdagh Bart Jacobs Fredrik T. Bosman Bengt Gustavsson Bernard Majoie Arnaud Roth Jo Vandesompele Isidore Rigoutsos Mauro Delorenzi Sabine Tejpar | 2012 | FEBS Letters2012，，19： | 3 |
| 3 | Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma显示文摘BACKGROUND Liver cancer is the fifth most common cancer and the second cause of cancerrelated deaths worldwide.Transarterial chemoembolization(TACE)is the best treatment of intermediate hepatocellular carcinoma(HCC).Doxorubicin is the most commonly used drug despite a low level of evidence.AIM To compare the objective response rate of idarubicin-based TACE(Ida-TACE)against doxorubicin-based TACE(Dox-TACE)in intermediate stage HCC.METHODS Between January 2012 and December 2014,all patients treated with TACE at our academic hospital were screened.Inclusion criteria were patients with Child-Pugh score A or B,a performance status below or equal to 1,and no prior TACE.Either lipiodol TACE or drug-eluting beads TACE could be performed with 10 mg of idarubicin or 50 mg of doxorubicin.Each patient treated with idarubicin was matched with two doxorubicin-treated patients.The TACE response was assessed by independent radiologists according to the mRECIST criteria.RESULTS Sixty patients were treated with doxorubicin and thirty with idarubicin.There were 93%and 87%of cirrhotic patients and 87%and 70%of Child-Pugh A in the doxorubicin and idarubicin groups,respectively.The median number of HCC per patient was two in both groups with 31%and 26%of single nodules in doxorubicin and idarubicin groups,respectively.Objective response rate after first TACE was 76.7%and 73.3%(P=0.797)with 41.7%and 40.0%complete response in doxorubicin and idarubicin groups,respectively.Progression-free survival was 7.7 mo in both groups,and liver transplant-free survival was 24.9 mo and 21.9 mo in doxorubicin and idarubicin groups,respectively.Safety profiles were similar in both groups,with grade 3-4 adverse events in 35%of Dox-TACE and 43%of Ida-TACEs.CONCLUSION Ida-TACE and Dox-TACE showed comparable results in terms of efficacy and safety.Ida-TACE may represent an interesting alternative to Dox-TACE in the management of patients with intermediate stage HCC. | Gael Stephane Roth Yann Teyssier Melodie Abousalihac Arnaud Seigneurin Julien Ghelfi Christian Sengel Thomas Decaens | 2020 | World Journal of Gastroenterology2020，26，3： | 3 |
| 4 | Survival after Lung Metastasectomy in Colorectal Cancer Patients with Previously Resected Liver Metastases显示文摘 | Michel Gonzalez John Henri Robert Nermin Halkic Gilles Mentha Arnaud Roth Thomas Perneger Hans Beat Ris Pascal Gervaz | 2012 | World Journal of Surgery2012，，2： | 2 |
| 5 | Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group显示文摘 | Eric Van Cutsem Cornelius Van de Velde Arnaud Roth Florian Lordick Claus-Henning K?hne Stefano Cascinu Matti Aapro | 2007 | European Journal of Cancer2007，，2： | 1 |
| 6 | A Survival Analysis of the Liver-First Reversed Management of Advanced Simultaneous Colorectal Liver Metastases: A LiverMetSurvey-Based Study显示文摘 | Axel Andres Christian Toso Rene Adam Eduardo Barroso Catherine Hubert Lorenzo Capussotti Eric Gerstel Arnaud Roth Pietro E. Majno Gilles Mentha | 2012 | Annals of Surgery2012，，5： | 1 |
| 7 | Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer显示文摘 | Eva Budinska Vlad Popovici Sabine Tejpar Giovanni D’Ario Nicolas Lapique Katarzyna Otylia Sikora Antonio Fabio Di Narzo Pu Yan John Graeme Hodgson Scott Weinrich Fred Bosman Arnaud Roth Mauro Delorenzi | 2013 | J. Pathol2013，，1： | 1 |
| 8 | Neoadjuvant radiochemotherapy for locally advanced gastric cancer: Long-term results of a phase I trial显示文摘 | Abdelkarim S. Allal Daniel Zwahlen Marie-Anne Bründler Raymond de Peyer Philippe Morel Olivier Huber Arnaud D. Roth | 2005 | International Journal of Radiation Oncology, Biology, Physics2005，，5： | 1 |
| 9 | Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer显示文摘 | Eva Budinska Vlad Popovici Sabine Tejpar Giovanni D’Ario Nicolas Lapique Katarzyna Otylia Sikora Antonio Fabio Di Narzo Pu Yan John Graeme Hodgson Scott Weinrich Fred Bosman Arnaud Roth Mauro Delorenzi | 2013 | J Pathol2013，，1： | 1 |
| 10 | Neoadjuvant Chemotherapy in Patients with Stage IV Colorectal Cancer: A Comparison of Histological Response in Liver Metastases, Primary Tumors, and Regional Lymph Nodes显示文摘 | Pascal Gervaz Laura Rubbia-Brandt Axel Andres Pietro Majno Arnaud Roth Philippe Morel Gilles Mentha | 2010 | Annals of Surgical Oncology2010，，10： | 1 |
| 11 | Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization显示文摘BACKGROUND At the diagnosis of hepatocellular carcinoma(HCC),more than 90%of HCC patients present cirrhosis,a clinical condition often associated to malnutrition.Sarcopenia is an indirect marker of malnutrition assessable on computed tomography(CT).AIM To evaluate the prognostic value of sarcopenia in patients with HCC treated by trans-arterial(chemo)-embolization.METHODS Patients with HCC treated by a first session of trans-arterial(chemo)embolization and an available CT scan before treatment were included.Sarcopenia was assessed using skeletal muscle index at baseline and at the first radiological assessment.Radiological response was recorded after the first session of treatment using mRECIST.RESULTS Of 225 patients treated by trans-arterial bland embolization(n=71)or trans-arterial chemoembolization(n=154)for HCC between 2007 and 2013,Barcelona Clinic of Liver Cancer stage was A,B,and C in 27.5%,55%,and 16.8%of cases,respectively.Sarcopenia was present in 57.7%of the patients.Patients with sarcopenia presented a higher rate of progressive disease(19%vs 8%,P=0.0236),a shorter progression-free survival(8.3 vs 13.2 mo,P=0.0035),and a shorter median overall survival(19.4 mo vs 35.5 mo,P=0.0149)compared with non-sarcopenic patients.Finally,patients whose sarcopenia appeared after first transarterial treatment had the worst prognosis(P=0.0004).CONCLUSION Sarcopenia is associated with tumor progression and poor survival outcomes after trans-arterial(chemo)-embolization for HCC. | Gael Roth Yann Teyssier Maxime Benhamou Mélodie Abousalihac Stefano Caruso Christian Sengel Olivier Seror Julien Ghelfi Arnaud Seigneurin Nathalie Ganne-Carrie Elia Gigante Lorraine Blaise Olivier Sutter Thomas Decaens Jean-Charles Nault | 2022 | World Journal of Gastroenterology2022，28，36： | 1 |
| 12 | Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis显示文摘 | Xavier Paoletti Koji Oba Yung-Jue Bang Harry Bleiberg Narikazu Boku Olivier Bouché Paul Catalano Nozomu Fuse Stefan Michiels Markus Moehler Satoshi Morita Yasuo Ohashi Atsushi Ohtsu Arnaud Roth Philippe Rougier Junichi Sakamoto Daniel Sargent Mitsuru Sasa | 2013 | JNCI Journal of the National Cancer Institute2013，，21： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员